Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma.
Purity:
95.00%
CAS Number:
[1924598-82-2]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted